Navigation Links
Argos Therapeutics Presents Data Showing Memory T Cell Expansion After Administration of Fully Personalized Immunotherapy Correlates with Overall Survival Benefit in Patients with Metastatic Renal Cell Carcinoma
Date:11/11/2013

ted with patient survival. 

"We believe that these additional findings from our Phase 2 trial support the in vivo mechanism of action of AGS-003," said Charles Nicolette, Argos' chief scientific officer and vice president of research and development, adding, "we also believe this is the first demonstration in a clinical trial that the magnitude of an adaptive immune response following immunotherapy correlates with prolonged survival."  

The Phase 2 clinical trial of AGS-003 in combination with sunitinib enrolled 21 intermediate and poor risk mRCC patients who had a time from diagnosis to initiation of systemic therapeutic treatment of less than one year. Fourteen of these patients were evaluable for immune responses, and median overall survival for these 14 patients was 39.5 months.

Earlier this year, Argos initiated a pivotal Phase 3 clinical trial for AGS-003 ("ADAPT"). The randomized, multicenter, open-label ADAPT clinical trial is designed to examine the potential for AGS-003 plus standard targeted drug therapy to extend OS versus standard therapy alone in newly diagnosed mRCC patients. Argos is using BTSVQ to analyze multi-color flow cytometry data in the ADAPT trial, which will enroll a total of 450 patients in approximately 130 global sites. 

About the Arcelis™ Technology Platform
Arcelis is a fully personalized immunotherapy technology that captures mutated and variant antigens that are specific to each patient's disease. It is designed to overcome immunosuppression by producing a durable memory T cell response without adjuvants that may be associated with toxicity. The technology is potentially applicable to a wide range of different cancers and infectious diseases and is designed to overcome many of the manufacturing and commercialization challenges that have impeded other personalized immunotherapies.

The Arcelis process uses only a small tumor or blood sampl
'/>"/>

SOURCE Argos Therapeutics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Argos Therapeutic Arcelis™ Immunotherapy AGS-003 in Combination With Sunitinib Shows Statistically Significant Correlation of Immune System Response to Overall Survival in Phase 2 Study in Patients with Advanced Renal Cell Carcinoma (RCC)
2. Global Aptamers Market Technology Trend Analysis Market Report 2013-2018: Therapeutics, Diagnostics, Biosensors, Biomarker/Drug Discovery & Applications
3. Acquisitions, Project Announcements & Trend Analysis News for Oxygen Biotherapeutics, Glu Mobile, Cisco Systems, Barrick Gold, CVS Caremark
4. Convoy Therapeutics Appoints Clinical Advisory Board
5. Aratana Therapeutics Inc. to Report Third Quarter 2013 Financial Results
6. United Therapeutics Corporation Reports Third Quarter 2013 Financial Results
7. The Zacks Analyst Blog Highlights: Eaton, Baxter International, Bio-Rad Laboratories, INSYS Therapeutics and Boston Scientific
8. Moderna Therapeutics Named to the World Economic Forums Community of "Global Growth Companies"
9. United Therapeutics Corporation to Announce Third Quarter 2013 Financial Results Before Market Open on Tuesday, October 29, 2013
10. PTC Therapeutics Expands Management Team
11. Relmada Therapeutics Inc. Completes $8.0 Million Capital Raise In Series A Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/30/2015)... England , August 31, 2015 ...   einer Frau   für chirurgische   Behandlung     ... von 7-90   werden für eine   verheerende ... 1200 Frauen behandeln und die Anzahl ausgebildeter Chirurgen in ... Astellas gab heute bekannt, dass  Action on Fistula ...
(Date:8/28/2015)... (PRWEB) , ... August 28, 2015 , ... ... Personalized Medicine, presented two studies at the International Spine Intervention Society’ ... 28th, 2015 through to August 1st, 2015. With a focus on evidence-based research ...
(Date:8/28/2015)... ... August 28, 2015 , ... ... surgeon, Wade McKenna, DO, announced today that the use of sterile, dehydrated amniotic ... complete healing of an otherwise non-healing surgical knee wound. , The case involved ...
(Date:8/27/2015)... (PRWEB) , ... August 27, 2015 , ... Capital ... solve complex business problems, is pleased to announce their ranking as one of the ... ranking of the fastest-growing private companies across the nation. , “It is truly an ...
Breaking Biology Technology:Über 550 Frauen, deren Leben durch "Action on Fistula" transformiert wurde 2Über 550 Frauen, deren Leben durch "Action on Fistula" transformiert wurde 3Über 550 Frauen, deren Leben durch "Action on Fistula" transformiert wurde 4Über 550 Frauen, deren Leben durch "Action on Fistula" transformiert wurde 5Proove Biosciences Presents New Research Study at the International Spine Intervention Society’s Annual Scientific Meeting 2Proove Biosciences Presents New Research Study at the International Spine Intervention Society’s Annual Scientific Meeting 3Proove Biosciences Presents New Research Study at the International Spine Intervention Society’s Annual Scientific Meeting 4Dallas-Fort Worth Stem Cell Researchers Use Amniotic Tissue To Successfully Treat Non-Healing Surgical Wound 2Dallas-Fort Worth Stem Cell Researchers Use Amniotic Tissue To Successfully Treat Non-Healing Surgical Wound 3Dallas-Fort Worth Stem Cell Researchers Use Amniotic Tissue To Successfully Treat Non-Healing Surgical Wound 4Capital Edge Consulting Makes Inc. 5000 List of America’s Fastest-Growing Private Companies 2Capital Edge Consulting Makes Inc. 5000 List of America’s Fastest-Growing Private Companies 3
... Corp . President Paul Shain spoke on his ... Madisons monthly meeting. According to Shain, Berbees unique principles and ... dot-com era as other information technology-focused companies failed. , ,Started ... founded on the dogma of creating an environment for success, ...
... Internet access is now a reality for one rural ... system. Toronto-based WaveRider Communications Inc. is working ... Oakdale Electric Cooperative to implement its Last Mile ... to broadband Internet services. , ,The response in Mauston ...
... a talk at my local elementary school given by Peter ... of systems thinking. Systems thinking is a conceptual framework, body ... years, to train people to see the big picture ... how to make systematic change successfully. The essence of systems ...
Cached Biology Technology:Berbees success is based on companys history and culture 2Berbees success is based on companys history and culture 3Berbees success is based on companys history and culture 4Rural Wisconsin town gets high-speed Internet access 2Outsourcing: Net gain or shifting the pain? 2Outsourcing: Net gain or shifting the pain? 3
(Date:8/10/2015)... TELTOW, Germany , August 10, 2015 ... a world leader in Eye Tracking Technology for more ... OEM Eye Tracking Platform for integration into all consumer ... reference designs for seamless integration of eye tracking into ... HMDs and augmented reality smart glasses. Omnivision,s leading sensor ...
(Date:8/6/2015)... , Aug. 6, 2015  Today, U.S. ... visit Crossmatch ™ to learn firsthand how ... protect data. Crossmatch is a world leader in ... and expertise are helping federal agencies and commercial ... security.   "The vast majority of ...
(Date:8/6/2015)... SAN JOSE, Calif. , Aug. 6, 2015 ... the leading developer of human interface solutions, today ... and TouchPad technologies on Windows 10. Microsoft leveraged ... fundamental to the operating system. ... and drivers are fully certified with Microsoft,s Precision ...
Breaking Biology News(10 mins):SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3Rep. Honda to Visit Crossmatch in Redwood City 2Synaptics Chosen for Human Interface Co-Development on Windows 10 2
... 27, 2013  Definiens, the global leader of image and ... it has appointed an Advisory Board comprising renowned industry ... its market expansion strategy, Definiens established the new Board ... tissue diagnostics and clinical digital pathology. Members of the ...
... caffeine, but scientists now have genetically engineered E. ... report in the journal ACS Synthetic Biology ... that promises practical uses ranging from decontamination of wastewater ... Barrick and colleagues note that caffeine and related chemical ...
... and the University of Oxford have been able to give ... provide paternal care. When the conditions are right, this strategy ... put a lot of effort into caring for offspring that ... sense at all because natural selection should design males to ...
Cached Biology News:Gilde Healthcare III Portfolio Company Definiens Establishes Advisory Board 2Gilde Healthcare III Portfolio Company Definiens Establishes Advisory Board 3Why sticking around is sometimes the better choice 2
Goat polyclonal to Centaurin alpha 2**...
... immobilization can be coupled with a ligand such ... create an affinity matrix of choice. Affi-Gel 10 ... amines. Affi-Gel 10 gel couples neutral or basic ... 15 gel couples acidic proteins with pI less ...
Rabbit anti Mouse ZIC2 Preservative: NaN3...
Monocarboxylate (lactate) transporter 2...
Biology Products: